Aqua Bio Technology ASA · OSL:ABTEC
Aqua Bio Technology ASA — Q1 2015 Earnings Presentation
11 slides from Aqua Bio Technology ASA's earnings presentation, May 13, 2015
Slide 1: First Quarter 2015 Results Presentation
First Quarter 2015 Results Presentation 13 May 2015 1
Slide 2: Q1 2015 Highlights
Q1 2015 Highlights • Revenue stream as agreed in exclusivity contracts • Second best quarterly result in Company history • Financial position further strengthened – NOK 34 million cash reserve
Slide 3: Income Statement
Income Statement NOK million Q1 2015 Q1 2014 FY 2014 Income 9.1 5.4 22.5 Operating costs -3.8 -4.2 -16.7 EBITDA 5.2 1.2 5.8 EBIT 3.6 -0.4 -0.5 EBT 4.1 -0.4 0.9 Net result 4.1 -0.4 0.9 EBITDA margin 57.7% 21.8% 26.0% • Royalty and exclusivity payments received according to contracts • Revenues may fl
Slide 4: Financial development last five quarters
Financial development last five quarters NOK 1.000 10000 6000 70,0 % 9000 5000 60,0 % 8000 7000 50,0 % 4000 6000 40,0 % 5000 3000 30,0 % 4000 2000 3000 20,0 % 2000 1000 10,0 % 1000 0 0,0 % 0 Q1 14 Q2 14 Q3 14 Q4 14 Q1 15 Q1 14 Q2 14 Q3 14 Q4 14 Q1 15 -1000 -10,0 % Other income Sales income EBITDA (N
Slide 5: Balance Sheet
Balance Sheet NOK million 31 Mar 2015 31 Dec 2014 31 Mar 2014 Fixed assets 11.3 12.4 16.4 Current assets 67.2 63.4 60.5 - of which is cash 33.8 29.2 26.6 Total equity 70.4 66.3 65.6 Long term debt 5.6 5.6 8.5 Short term debt 2.5 3.9 2.8 Total balance 78.5 75.8 76.9 Equity ratio 89.7% 73.8% 85.3%
Slide 6: Cash flow
Cash flow NOK million (Year to date) 2015 2014 Cash at beginning of period 29.2 27.0 From operations 4.7 1.5 From investments -0.5 -1.4 From financing -0.1 -0.6 Currency effects 0.5 0.0 Cash at end of period 33.8 26.6 Cash change in period 4.1 -0.4
Slide 7: A strategy for expansion
A strategy for expansion 1. Support exclusivity partners Restorsea and Amway in their efforts to Ongoing reach commercial success in the cosmetics market with skin care products based on ABT technology. 2. Active in-licensing of relevant technologies from partners; develop Ongoing ABT as a powerhous
Slide 8: Addressing a broader market
Addressing a broader market • ABT ingredients for medical purposes to be explored • ABTs key personnel have experience from the pharmaceutical industry • Natural and sustainable ingredients in demand also by medical/OTC products manufacturers 8
Slide 9: Outlook
Outlook • Continued strong revenue stream – Commercial success of exclusivity partners represent upside potential – Operating costs expected back to normal levels – Limited marketing costs expected in first half 2015 • Strategy of broadened market approach holds potential – Search, and evaluation of
Slide 10: 2nd Quarter 2015 Results 19 August 2015
2nd Quarter 2015 Results 19 August 2015
Slide 11: Investor contact
Investor contact Arvid Lindberg, CEO +47 9824 5410 arvid@aquabiotech.no www.aquabiotechnology.com